CAMPATH: from concept to clinic.

Journal article

Lymphocyte depletion has a long history in the area of therapeutic immunosuppression. CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has established it as a licensed drug for the management of chronic lymphocyte leukaemia. Short-term therapy with alemtuzumab has demonstrated long-term benefit in a number of autoimmune conditions. This drug has the potential to facilitate recruitment of tolerance processes so enabling drug minimization in transplantation, autoimmune and hypersensitivity diseases.

Authors: Waldmann, H; Hale, G

• Publication status: Published
• Journal: Philosophical transactions of the Royal Society of London. Series B, Biological sciences
• Volume: 360
• Issue: 1461
• Pages: 1707-1711
• Publication date: 2005-09-01
• DOI: 10.1098/rstb.2005.1702
• EISSN: 1471-2970
• ISSN: 0962-8436
• Language: English
• Keywords: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Models, Immunological; Immune Tolerance; Antibodies, Neoplasm; Lymphocyte Depletion; Graft vs Host Disease; T-Lymphocytes; Animals; Humans